Mucus structure and properties in cystic fibrosis
- PMID: 17419972
- DOI: 10.1016/j.prrv.2007.02.004
Mucus structure and properties in cystic fibrosis
Abstract
The biophysical properties of airway secretions are largely determined by the polymeric components. In normal airway mucus, the gel-forming mucins, MUC5AC and MUC5B, are responsible not only for the viscoelastic properties essential for clearance and protecting the airway epithelium from invaders and water evaporation. With chronic airway infection, inflammatory cell necrosis leads to a predominance of polymeric DNA and F-actin. There is almost no mucin in the sputum of patients with established cystic fibrosis lung disease. Sputum viscoelastic and surface properties determine how well secretions can be cleared by cilia or cough. In this mini-Symposium on Airway Clearance in Cystic Fibrosis, the physiology of CF secretion structure and rheology is discussed in the context of medications and physical maneuvers for enhancing sputum clearance.
Similar articles
-
Physiology of airway mucus clearance.Respir Care. 2002 Jul;47(7):761-8. Respir Care. 2002. PMID: 12088546 Review.
-
MUC5AC and MUC5B Mucins Are Decreased in Cystic Fibrosis Airway Secretions.Am J Respir Cell Mol Biol. 2004 Jul;31(1):86-91. doi: 10.1165/rcmb.2003-0345OC. Epub 2004 Feb 26. Am J Respir Cell Mol Biol. 2004. PMID: 14988081
-
MUC5AC and MUC5B mucins increase in cystic fibrosis airway secretions during pulmonary exacerbation.Am J Respir Crit Care Med. 2007 Apr 15;175(8):816-21. doi: 10.1164/rccm.200607-1011OC. Epub 2007 Jan 25. Am J Respir Crit Care Med. 2007. PMID: 17255563
-
The pharmacologic approach to airway clearance: mucoactive agents.Respir Care. 2002 Jul;47(7):818-22. Respir Care. 2002. PMID: 12088552 Review.
-
Mucolytics, expectorants, and mucokinetic medications.Respir Care. 2007 Jul;52(7):859-65. Respir Care. 2007. PMID: 17594730
Cited by
-
Dry powder aerosol containing muco-inert particles for excipient enhanced growth pulmonary drug delivery.Nanomedicine. 2020 Oct;29:102262. doi: 10.1016/j.nano.2020.102262. Epub 2020 Jul 3. Nanomedicine. 2020. PMID: 32623017 Free PMC article.
-
Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery.J Control Release. 2020 Oct 10;326:222-244. doi: 10.1016/j.jconrel.2020.07.011. Epub 2020 Jul 16. J Control Release. 2020. PMID: 32681948 Free PMC article. Review.
-
Inflammation as a Regulator of the Airway Surface Liquid pH in Cystic Fibrosis.Cells. 2023 Apr 7;12(8):1104. doi: 10.3390/cells12081104. Cells. 2023. PMID: 37190013 Free PMC article. Review.
-
Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs.Nat Biomed Eng. 2021 Sep;5(9):1059-1068. doi: 10.1038/s41551-021-00786-x. Epub 2021 Oct 6. Nat Biomed Eng. 2021. PMID: 34616046 Free PMC article.
-
Mesoscopic modeling as a starting point for computational analyses of cystic fibrosis as a systemic disease.Biochim Biophys Acta. 2014 Jan;1844(1 Pt B):258-70. doi: 10.1016/j.bbapap.2013.03.023. Epub 2013 Apr 6. Biochim Biophys Acta. 2014. PMID: 23570976 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical